Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Rating of "Hold" by Brokerages

Key Points

• Analysts assign Intellia a consensus rating of "Hold" from 20 brokerages (2 sell, 8 hold, 9 buy, 1 strong buy) with an average 1‑year price objective of $19.52.
• Several firms have recently increased targets or upgraded the stock—HC Wainwright raised its target to $30, JonesTrading upgraded to Buy with a $29 target, and Leerink raised its target to $29, indicating rising analyst enthusiasm.
• Intellia beat quarterly estimates (EPS loss of $0.83 vs. $0.99 expected and revenue $23.02M, up 78% YoY) but remains unprofitable with negative margins; the stock trades near $13.63 with a $1.61B market cap and institutional investors own about 88.8% of shares.

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) have earned an average rating of "Hold" from the twenty brokerages that are covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $19.5238.

NTLA has been the subject of several research reports. Bank of America reiterated a "neutral" rating on shares of Intellia Therapeutics in a research report on Monday, March 2nd. HC Wainwright raised their price objective on Intellia Therapeutics from $25.00 to $30.00 and gave the stock a "buy" rating in a research note on Tuesday, March 3rd. JonesTrading raised shares of Intellia Therapeutics from a "hold" rating to a "buy" rating and set a $29.00 price objective for the company in a report on Wednesday, March 4th. Wall Street Zen upgraded shares of Intellia Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, March 7th. Finally, Leerink Partners increased their target price on shares of Intellia Therapeutics from $27.00 to $29.00 and gave the stock an "outperform" rating in a report on Tuesday, March 3rd.

Institutional Investors Weigh In On Intellia Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Pictet Asset Management Holding SA lifted its holdings in Intellia Therapeutics by 47.2% in the first quarter. Pictet Asset Management Holding SA now owns 16,933 shares of the company's stock worth $217,000 after acquiring an additional 5,429 shares during the last quarter. Lewis Asset Management LLC grew its holdings in shares of Intellia Therapeutics by 38.5% during the first quarter. Lewis Asset Management LLC now owns 19,770 shares of the company's stock valued at $253,000 after purchasing an additional 5,500 shares during the last quarter. SG Americas Securities LLC grew its holdings in shares of Intellia Therapeutics by 22.6% during the first quarter. SG Americas Securities LLC now owns 89,688 shares of the company's stock valued at $1,150,000 after purchasing an additional 16,545 shares during the last quarter. Rockefeller Capital Management L.P. raised its position in shares of Intellia Therapeutics by 1.7% during the 4th quarter. Rockefeller Capital Management L.P. now owns 140,218 shares of the company's stock worth $1,261,000 after purchasing an additional 2,277 shares during the period. Finally, Virtu Financial LLC acquired a new stake in shares of Intellia Therapeutics during the 4th quarter worth approximately $245,000. Institutional investors and hedge funds own 88.77% of the company's stock.

Intellia Therapeutics Stock Performance

Shares of NTLA stock opened at $13.63 on Friday. The stock has a market capitalization of $1.61 billion, a price-to-earnings ratio of -3.56 and a beta of 1.99. Intellia Therapeutics has a one year low of $6.83 and a one year high of $28.25. The company's 50-day simple moving average is $13.57 and its 200-day simple moving average is $13.10.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.83) earnings per share for the quarter, beating the consensus estimate of ($0.99) by $0.16. Intellia Therapeutics had a negative return on equity of 56.81% and a negative net margin of 609.85%.The firm had revenue of $23.02 million during the quarter, compared to analyst estimates of $12.17 million. During the same period in the previous year, the company earned ($1.27) earnings per share. Intellia Therapeutics's quarterly revenue was up 78.4% on a year-over-year basis. As a group, research analysts forecast that Intellia Therapeutics will post -3.53 EPS for the current year.

About Intellia Therapeutics

Intellia Therapeutics, Inc NASDAQ: NTLA is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company's research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia's lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.